Study of Abiraterone Acetate, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04262154 |
Recruitment Status :
Recruiting
First Posted : February 10, 2020
Last Update Posted : November 30, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Metastatic Prostate Cancer | Drug: Atezolizumab Drug: Abiraterone Drug: Prednisone Drug: Lupron Radiation: Stereotactic Body Radiotherapy (SBRT) | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 44 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | SAABR: Single Arm Phase II Study of Abiraterone + Atezolizumab + GnRH Analog and Stereotactic Body Radiotherapy (SBRT) to the Prostate in Men With Newly Diagnosed Hormone-sensitive Metastatic Prostate Cancer |
Actual Study Start Date : | March 3, 2020 |
Estimated Primary Completion Date : | September 2022 |
Estimated Study Completion Date : | September 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: Metastatic Prostate Cancer
Participants will have untreated metastatic (M1a/b/c) hormone-sensitive prostate cancer documented by positive bone scan or metastatic lesion on CT or MRI; untreated is defined as having never received surgical, radiotherapeutic, or systemic therapy for their prostate cancer.Group 1 and 2. The first 20 patients enrolled will be in Group 1 and the remaining patients (and those who are already on a GnRH analog) will be assigned to Group 2. All study participants will receive treatment with atezolizumab, abiraterone acetate, prednisone, GnRH analog, and SBRT, at the same doses.
|
Drug: Atezolizumab
Atezolizumab 1200 mg IV over 60 minutes every 3 weeks Drug: Abiraterone Abiraterone 1000 mg daily Drug: Prednisone Prednisone 5 mg daily Drug: Lupron Lupron 22.5 mg IM injection every 3 months Radiation: Stereotactic Body Radiotherapy (SBRT) Intensity-modulated, image-guided, ultra-hypofractionated external beam radiotherapy (7.25-7.5 Gy x 5 to prostate and seminal vesicles QOD) will begin around 12 weeks (at Cycle 5 Day 1 (+/-5 days) |
- Failure-free rate at 2 years [ Time Frame: 2 years ]Failure is defined as: biochemical failure, radiographic progression defined by PCWG3, or death from any cause.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Willing and able to provide or have a legally authorized representative to provide written informed consent and HIPAA authorization for the release of personal health information. A signed informed consent must be obtained before screening procedures are performed.
NOTE: HIPAA authorization may be either included in the informed consent or obtained separately.
- Males 18 years of age and above
- Untreated metastatic (M1a/b/c) hormone-sensitive prostate cancer documented by positive bone scan or metastatic lesion on CT or MRI; untreated is defined as having never received surgical, radiotherapeutic, or systemic therapy for their prostate cancer.
- Biopsy-proven adenocarcinoma of the prostate
- Eligible for SBRT per institutional guidelines
- ECOG status of 0 or 1
- Normal organ function with acceptable initial laboratory values within 14 days of treatment start:
ANC ≥ 1,500 /µl Albumin ≥ 3.5 g/dL Hemoglobin ≥ 9 g/dL Platelet count ≥ 100,000 /µl Creatinine > 30 mL/min (calculated using the Cockcroft-Gault Clearance formula) Potassium ≥ 3.5 mmol/L(within institutional normal range) Bilirubin < 1.5 x ULN (unless documented Gilbert's disease) SGOT(AST) < 1.5 x ULN SGPT(ALT) < 1.5 x ULN INR ≤ 1.5 x ULN
- Subjects must agree to use a medically acceptable method of birth control (e.g., spermicide in conjunction with a barrier such as a condom) or sexual abstinence for the duration of the study, including 150 days after the last dose of study drug. Sperm donation is prohibited during the study and for 30 days after the last dose of study drug. Female partners must use hormonal or barrier contraception unless postmenopausal or abstinent.
Exclusion Criteria:
- History of malignancy within 3 years prior to initiation of study treatment, except for malignancies with a negligible risk of metastasis of dead (e.g., 5-year OS rate >90%), such as non-melanoma skin carcinoma
- Pathological finding consistent with pure small cell carcinoma of the prostate
- Prostate volume > 80 cc
- Known or suspected brain metastasis or active leptomeningeal disease
- Asymptomatic lesions that would likely cause functional deficits or intractable pain with further growth (e.g. clinically significant epidural disease, structurally unstable bone lesions)
- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (one monthly or more frequently).
- Uncontrolled hypertension (systolic blood pressure ≥160 mmHg or diastolic BP ≥95 mmHg). Subjects with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatment
- Positive HIV test at screening
- Active hepatitis C virus (HCV) infection, defined as having a positive HCV antibody test followed by a positive HCV RNA test at screening. The HCV RNA test will be performed only for subjects who have a positive HCV antibody test.
- History of adrenal dysfunction
- Uncontrolled or symptomatic hypercalcemia (ionized calcium >1.5 mmol/L, calcium > 12 mg/dL or corrected serum calcium > ULN)
-
Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjogren syndrome, Guillain-Barre syndrome, or multiple sclerosis, with the following exceptions:
- Subjects with a history of autoimmune-related hypothyroidism who are on thyroid replacement hormone
- Subjects with controlled Type 1 diabetes mellitus who are on an insulin regimen
- Subjects with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., subjects with psoriatic arthritis are excluded) are allowed provided all the following conditions are met:
- Rash must cover < 10% of body surface area
- Disease is well controlled at baseline and requires only low-potency topical corticosteroids
- No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high potency or oral corticosteroids within the previous 12 months
- History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
- Active tuberculosis
- Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, cerebrovascular accident, unstable arrhythmia or unstable angina) within 6 months prior to initiation of study treatment
- Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study
- Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia
-
Prior allogeneic stem cell or solid organ transplantation
- Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the final dose of atezolizumab
- Treatment with investigational therapy within 28 days prior to initiation of study treatment
- Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies
- Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin 2 [IL-2]) within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of study treatment
-
Treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF-a agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment, with the following exceptions:
- Subjects who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) are eligible for the study after Sponsor Principal Investigator approval has been obtained.
- Subjects who received mineralocorticoids (e.g., fludrocortisone), corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the study
- History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins
- Known hypersensitivity to Chinese hamster ovary cell products or to any component of the atezolizumab formulation
- Known allergy or hypersensitivity to any component of the abiraterone or prednisone formulations
- Any other disease, metabolic dysfunction, physical examination finding, clinical laboratory finding or situation that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the subject at high risk from treatment complications

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04262154
Contact: Dana Rathkopf, MD | 646-422-4379 | rathkopd@mskcc.org | |
Contact: Sean McBride, MD | 212-639-5717 | mcbrides@mskcc.org |
United States, New Jersey | |
Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities) | Recruiting |
Basking Ridge, New Jersey, United States, 07920 | |
Contact: Dana Rathkopf, MD 646-422-4379 | |
Memoral Sloan Kettering Monmouth (Limited Protocol Activities) | Recruiting |
Middletown, New Jersey, United States, 07748 | |
Contact: Dana Rathkopf, MD 646-422-4379 | |
Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Recruiting |
Montvale, New Jersey, United States, 07645 | |
Contact: Dana Rathkopf, MD 646-422-4379 | |
United States, New York | |
Memorial Sloan Kettering Cancer Commack (Limited Protocol Activities) | Recruiting |
Commack, New York, United States, 11725 | |
Contact: Dana Rathkopf, MD 646-422-4379 | |
Memoral Sloan Kettering Westchester (Limited Protocol Activities) | Recruiting |
Harrison, New York, United States, 10604 | |
Contact: Dana Rathkopf, MD 646-422-4379 | |
Columbia University | Not yet recruiting |
New York, New York, United States, 10032 | |
Contact: Jessica Hawley, MD 646-863-5502 | |
Memorial Sloan Kettering Cancer Center | Recruiting |
New York, New York, United States, 10065 | |
Contact: Dana Rathkopf, MD 646-422-4379 | |
Memorial Sloan Kettering Nassau (Limited Protocol Activities) | Recruiting |
Uniondale, New York, United States, 11553 | |
Contact: Dana Rathkopf, MD 646-422-4379 |
Principal Investigator: | Dana Rathkopf, MD | Memorial Sloan Kettering Cancer Center |
Responsible Party: | Memorial Sloan Kettering Cancer Center |
ClinicalTrials.gov Identifier: | NCT04262154 |
Other Study ID Numbers: |
19-461 |
First Posted: | February 10, 2020 Key Record Dates |
Last Update Posted: | November 30, 2020 |
Last Verified: | November 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org. |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Abiraterone Acetate Atezolizumab GnRH Analog Radiation Therapy Hormone sensitive prostate cancer |
Stereotactic Body Radiotherapy SBRT Metastatic prostate cancer 19-461 Memorial Sloan Kettering Cancer Center |
Prostatic Neoplasms Hypersensitivity Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site Neoplasms Prostatic Diseases Immune System Diseases Prednisone |
Atezolizumab Anti-Inflammatory Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Antineoplastic Agents, Hormonal Antineoplastic Agents |